160 related articles for article (PubMed ID: 12457721)
1. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells.
Mihara M; Shintani S; Nakashiro K; Hamakawa H
Oral Oncol; 2003 Jan; 39(1):49-55. PubMed ID: 12457721
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
5. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.
Li Y; Chinni SR; Senderowicz AM; Sarkar FH
Int J Oncol; 2000 Oct; 17(4):755-9. PubMed ID: 10995888
[TBL] [Abstract][Full Text] [Related]
6. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.
König A; Schwartz GK; Mohammad RM; Al-Katib A; Gabrilove JL
Blood; 1997 Dec; 90(11):4307-12. PubMed ID: 9373241
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
14. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
16. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.
Semenov I; Akyuz C; Roginskaya V; Chauhan D; Corey SJ
Leuk Res; 2002 Mar; 26(3):271-80. PubMed ID: 11792416
[TBL] [Abstract][Full Text] [Related]
18. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland PJ; Pestell R; Albanese C; Sausville EA; Senderowicz AM
Cancer Res; 1999 Sep; 59(18):4634-41. PubMed ID: 10493518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
